InDex Pharmaceuticals Holding AB (publ) Interim Report January - September 2019.

STOCKHOLM: "Something that really differentiates cobitolimod from its competitors is the superior safety profile. Both the approved drugs and those currently being tested in phase III are associated with serious side effects. With an outstanding combination of efficacy and safety, cobitolimod is set to take a leading position within the field," said Peter Zerhouni, CEO of InDex Pharmaceuticals.

Period July - September 2019

Revenues amounted to SEK 0.0 (0.0) million

Operating result amounted to SEK -27.2 (-15.1) million

Result after tax amounted to SEK -27.2 (-15.1) million, corresponding to SEK -0.39 per share (-0.24) before and after dilution

Cash flow from operating activities amounted to SEK -19.1 (-16.1) million

Period January - September 2019

Revenues amounted to SEK 0.1 (0.1) million

Operating result amounted to SEK -62.1 (-59.9) million

Result after tax amounted to SEK -62.2 (-59.9) million, corresponding to SEK -0.90 per share (-0.96) before and after dilution

Cash flow from operating activities amounted to SEK -51.6 (-58.6) million

Cash and cash equivalents at the end of the period amounted to SEK 117.6 (66.4) million

Number of employees at the end of the period was 7 (7)

Number of shares at the end of the period was 82,537,530

All comparative amounts in brackets refer to the outcome during the corresponding period 2018.

Significant events during July - September 2019

The phase IIb study CONDUCT met the primary endpoint.

InDex updated the list of shareholders on the homepage with information as of August 30, 2019.

InDex completed a directed share issue of approximately SEK 140 million.

InDex announced notice of an extraordinary general meeting.

Significant events after the reporting period

InDex held an extraordinary general meeting, which resolved to approve the Board's resolution on a new issue of shares with deviation from the shareholders' preferential rights.

InDex updated the list of shareholders on the homepage with information as of October 18, 2019.

CEO statement

On August 27, we had the great pleasure of reporting successful top line results in the phase IIb study CONDUCT with cobitolimod. The study met the primary endpoint with a competitive efficacy and superior safety profile. Now it is full speed ahead towards phase III.

The CONDUCT study was an exploratory study to find the best dose to move forward in development, and the study clearly showed that the highest dose was the most effective. As in previous studies...